
Collaboration - June 8, 2016
AZ, Foundation Medicine enter strategic collaboration
AstraZeneca has entered into a definitive agreement with Foundation Medicine, Inc. (Foundation Medicine) to develop a novel companion diagnostic assay for Lynparza (olaparib) to support its global development programme. The companion diagnostic will enable physicians to identify those patients most likely to benefit from AstraZeneca’s first-in-class poly ADP-ribose polymerase (PARP) inhibitor. Lynparza is an innovative, […]